SkinBioTherapeutics plc (AIM:SBTX)
10.00
+0.50 (5.26%)
Jun 16, 2026, 12:35 PM GMT
SkinBioTherapeutics Balance Sheet
Financials in millions GBP. Fiscal year is July - June.
Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 3.12 | 4.78 | 0.8 | 1.31 | 1.8 | 4.61 |
Cash & Short-Term Investments | 3.12 | 4.78 | 0.8 | 1.31 | 1.8 | 4.61 |
Cash Growth | 152.61% | 496.75% | -38.95% | -27.32% | -60.85% | 113.51% |
Accounts Receivable | 0.76 | 0.62 | 0.28 | 0 | 0 | - |
Other Receivables | - | 0.79 | 0.06 | 0.3 | 0.33 | 0.21 |
Receivables | 0.76 | 1.41 | 0.34 | 0.3 | 0.33 | 0.21 |
Inventory | 0.93 | 0.8 | 0.47 | 0.03 | 0.12 | - |
Prepaid Expenses | - | 0.12 | 0.06 | 0.07 | 0.08 | 0.24 |
Total Current Assets | 4.81 | 7.11 | 1.67 | 1.72 | 2.33 | 5.06 |
Property, Plant & Equipment | 0.67 | 0.73 | 0.12 | 0.17 | 0.13 | 0.14 |
Goodwill | 2.42 | 2.42 | 2.04 | - | - | - |
Other Intangible Assets | 1.71 | 1.87 | 1.39 | 0.7 | 0.63 | 0.53 |
Total Assets | 9.6 | 12.13 | 5.22 | 2.59 | 3.08 | 5.73 |
Accounts Payable | 0.65 | 0.51 | 0.28 | 0.19 | 0.07 | 0.08 |
Accrued Expenses | - | 0.34 | 0.21 | 0.3 | 0.37 | 0.28 |
Short-Term Debt | - | - | 0.74 | - | - | - |
Current Portion of Leases | 0.1 | 0.11 | 0.04 | 0.03 | 0.03 | 0.03 |
Current Income Taxes Payable | 0.03 | 0.03 | 0.03 | - | 0.03 | 0.02 |
Other Current Liabilities | - | 0.47 | 0.5 | 0 | 0.01 | 0 |
Total Current Liabilities | 0.78 | 1.47 | 1.8 | 0.53 | 0.51 | 0.4 |
Long-Term Debt | 0.6 | 0.6 | - | - | - | - |
Long-Term Leases | 0.24 | 0.28 | 0.04 | 0.07 | 0.1 | 0.11 |
Long-Term Deferred Tax Liabilities | - | 0.36 | 0.15 | - | - | - |
Other Long-Term Liabilities | - | - | 0.25 | - | - | - |
Total Liabilities | 1.63 | 2.71 | 2.25 | 0.6 | 0.61 | 0.52 |
Common Stock | 2.59 | 2.59 | 2.02 | 1.73 | 1.57 | 1.57 |
Additional Paid-In Capital | 21.09 | 21.09 | 14.51 | 10.95 | 8.76 | 8.76 |
Retained Earnings | -16.14 | -14.7 | -14 | -11.12 | -8.29 | -5.5 |
Comprehensive Income & Other | 0.44 | 0.44 | 0.44 | 0.44 | 0.44 | 0.38 |
Shareholders' Equity | 7.98 | 9.42 | 2.97 | 1.99 | 2.48 | 5.22 |
Total Liabilities & Equity | 9.6 | 12.13 | 5.22 | 2.59 | 3.08 | 5.73 |
Total Debt | 0.94 | 0.99 | 0.82 | 0.1 | 0.13 | 0.14 |
Net Cash (Debt) | 2.19 | 3.79 | -0.02 | 1.21 | 1.68 | 4.47 |
Net Cash Growth | 938.28% | - | - | -27.78% | -62.48% | 107.04% |
Net Cash Per Share | 0.01 | 0.02 | -0.00 | 0.01 | 0.01 | 0.03 |
Filing Date Shares Outstanding | 259.17 | 258.78 | 202.26 | 173.14 | 156.78 | 156.78 |
Total Common Shares Outstanding | 258.78 | 258.78 | 202.26 | 173.14 | 156.78 | 156.78 |
Working Capital | 4.02 | 5.64 | -0.13 | 1.19 | 1.82 | 4.66 |
Book Value Per Share | 0.03 | 0.04 | 0.01 | 0.01 | 0.02 | 0.03 |
Tangible Book Value | 3.85 | 5.13 | -0.46 | 1.29 | 1.85 | 4.69 |
Tangible Book Value Per Share | 0.01 | 0.02 | -0.00 | 0.01 | 0.01 | 0.03 |